-
Je něco špatně v tomto záznamu ?
Antitumor activity of N-acetyl-D-glucosamine-substituted glycoconjugates and combined therapy with keyhole limpet hemocyanin in B16F10 mouse melanoma model
Hulíková K, Grobárová V, Křivohlavá R, Fišerová A.
Jazyk angličtina Země Česko
- MeSH
- acetylglukosamin chemie MeSH
- adjuvancia imunologická terapeutické užití MeSH
- antitumorózní látky terapeutické užití MeSH
- financování organizované MeSH
- glykokonjugáty chemie terapeutické užití MeSH
- hemokyanin terapeutické užití MeSH
- kombinovaná farmakoterapie MeSH
- lidé MeSH
- melanom farmakoterapie patologie MeSH
- modely nemocí na zvířatech MeSH
- myši inbrední C57BL MeSH
- myši MeSH
- nádorové buněčné linie MeSH
- nádory kůže farmakoterapie patologie MeSH
- synergismus léků MeSH
- výsledek terapie MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- myši MeSH
- zvířata MeSH
N-Acetyl-D-glucosamine-substituted glycoconjugates (GCJs) with the polyamidoamine (GN8P) or calix[4]arene (GN4C) scaffold represent ligands for NKR-P1 molecule and induce NK cell-mediated cytotoxicity in vitro. The in vivo effect of these GCJs on mouse melanoma model was determined when administered either alone or in combination with non-specific immunostimulator keyhole limpet hemocyanin (KLH). All types of treatment significantly reduced the tumor growth on day 23, while GN4C as well as KLH were effective continuously (from day 14). The GN4C also induced the longest mean survival time (46.3 ± 11.1 d), followed by KLH+GN4C (36.4 ± 12.1), KLH (35.6 ± 6.5), KLH+GN8P (35.6 ± 6.7), and GN8P (32.4 ± 7.0), compared to controls (29.8 ± 3.6). The B16F10 specific cytotoxicity of peripheral blood cells was significantly elevated by both KLH and GN8P, whereas not by GN4C. KLH increased the effect of the GN4C, but did not influence that of GN8P. GN4C was proved to exert anticancer activity in mouse melanoma model. The combination of KLH with GCJs did not generate synergism.
Lit.: 19
- 000
- 00000naa 2200000 a 4500
- 001
- bmc10032421
- 003
- CZ-PrNML
- 005
- 20111210195722.0
- 008
- 101118s2010 xr e eng||
- 009
- AR
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Hulíková, Katarína. $7 _AN043256
- 245 10
- $a Antitumor activity of N-acetyl-D-glucosamine-substituted glycoconjugates and combined therapy with keyhole limpet hemocyanin in B16F10 mouse melanoma model / $c Hulíková K, Grobárová V, Křivohlavá R, Fišerová A.
- 314 __
- $a Laboratory of Natural Immunity, Department of Immunology and Gnotobiology, Institute of Microbiology, v.v.i., Academy of Sciences of Czech Republic, Prague 4
- 504 __
- $a Lit.: 19
- 520 9_
- $a N-Acetyl-D-glucosamine-substituted glycoconjugates (GCJs) with the polyamidoamine (GN8P) or calix[4]arene (GN4C) scaffold represent ligands for NKR-P1 molecule and induce NK cell-mediated cytotoxicity in vitro. The in vivo effect of these GCJs on mouse melanoma model was determined when administered either alone or in combination with non-specific immunostimulator keyhole limpet hemocyanin (KLH). All types of treatment significantly reduced the tumor growth on day 23, while GN4C as well as KLH were effective continuously (from day 14). The GN4C also induced the longest mean survival time (46.3 ± 11.1 d), followed by KLH+GN4C (36.4 ± 12.1), KLH (35.6 ± 6.5), KLH+GN8P (35.6 ± 6.7), and GN8P (32.4 ± 7.0), compared to controls (29.8 ± 3.6). The B16F10 specific cytotoxicity of peripheral blood cells was significantly elevated by both KLH and GN8P, whereas not by GN4C. KLH increased the effect of the GN4C, but did not influence that of GN8P. GN4C was proved to exert anticancer activity in mouse melanoma model. The combination of KLH with GCJs did not generate synergism.
- 650 _2
- $a financování organizované $7 D005381
- 650 _2
- $a acetylglukosamin $x chemie $7 D000117
- 650 _2
- $a adjuvancia imunologická $x terapeutické užití $7 D000276
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a antitumorózní látky $x terapeutické užití $7 D000970
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a modely nemocí na zvířatech $7 D004195
- 650 _2
- $a synergismus léků $7 D004357
- 650 _2
- $a kombinovaná farmakoterapie $7 D004359
- 650 _2
- $a glykokonjugáty $x chemie $x terapeutické užití $7 D006001
- 650 _2
- $a hemokyanin $x terapeutické užití $7 D006433
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a melanom $x farmakoterapie $x patologie $7 D008545
- 650 _2
- $a myši $7 D051379
- 650 _2
- $a myši inbrední C57BL $7 D008810
- 650 _2
- $a nádory kůže $x farmakoterapie $x patologie $7 D012878
- 650 _2
- $a výsledek terapie $7 D016896
- 700 1_
- $a Grobárová, Valérie. $7 _AN055573
- 700 1_
- $a Křivohlavá, Romana. $7 _AN055574
- 700 1_
- $a Fišerová, Anna $7 xx0074790
- 773 0_
- $w MED00011005 $t Folia microbiologica $g Roč. 55, č. 5 (2010), s. 528-532 $x 0015-5632
- 910 __
- $a ABA008 $b A 2403 $c 561 $y 6
- 990 __
- $a 20101111142234 $b ABA008
- 991 __
- $a 20110624111248 $b ABA008
- 999 __
- $a ok $b bmc $g 820179 $s 685923
- BAS __
- $a 3
- BMC __
- $a 2010 $b 55 $c 5 $d 528-532 $m Folia microbiologica $x MED00011005
- LZP __
- $a 2010-31/mkme